GENSCRIPT BIO News

BOC International: Maintaining Kingsley Biotech's (01548) “Buy” Rating Target Price of HK$27.75

Zhitong Finance10:53

Kingsley Biotech (1548.HK): Approved for major indications, rapid release of CARVYKTI can be expected; focus on centralized implementation of 2H catalysts

交銀國際Apr 24 00:00

Kingsley Biotechnology (01548.HK): The legendary biological CARVYKTI is the world's first BCMA-targeted therapy approved as MM second-line treatment

國聯證券Apr 7 18:31

Kingsley Biotechnology (01548.HK): Cell therapy+life science two-wheel drive CGT industry chain leader

國聯證券Mar 29 17:06

Changes in Hong Kong stocks | Kingsley Biotech (01548) fell more than 7%, and CDMO short-term demand and profitability may be under pressure, CICC lowered the company's earnings estimates and target prices

Zhitong FinanceMar 19 15:23

Kingsley Biotechnology (1548.HK) Company Review: CARVYKTI was recommended by ODAC for early treatment to accelerate frontline expansion and production capacity increase

民生證券Mar 17 07:16

Dongwu Securities: Maintaining Kingsley Biotech's (01548) “Buy” Rating FY24Q2 Single Quarter Gross Margin Record High

Zhitong FinanceMar 15 09:36

Kingsley Biotech (1548.HK) 2023 Review: Life Science Business Shows Resilience, Continued Commercialization of CARVYKTI, Optimism, Frontline Treatment Approval

海通國際Mar 15 00:00

Kingsley Biotech (01548.HK): Business blossomed at multiple points and rapid growth in performance

東吳證券Mar 14 13:32

Kingsley Biotech (1548.HK) 2023 Annual Report Review: Life Science Business Development Steady, Rapid Release of Cell Therapy Products

光大證券Mar 13 11:26

Bank Rating | BOC International: Raising Kingsley Biotech's Target Price to HK$27.6 Rating “Buy”

Gelonghui FinanceMar 13 10:11

BOC International: Maintaining Kingsley Biotech's (01548) “Buy” Rating Target Price of HK$27.75

Zhitong FinanceMar 12 15:44

Kingsley Biotech (1548.HK): 2023 performance shows resilience amid industry fluctuations, bottoming out in 2024, and can be expected to raise the target price

交銀國際Mar 12 15:41

Yamato: Giving Kingsley Biotech (01548) a “buy” rating to improve gross margin in the second half of 2023

Zhitong FinanceMar 12 14:14

Kingsley Biotechnology (01548.HK): Life Sciences Profitability Improves Expectations for CARVYKTI Release

中金公司Mar 12 07:46

Kingsley Biotechnology (1548.HK): CILTA-CEL continues to release the four-in-one at high speed, and can be expected in the future

西南證券Mar 12 00:00

BOC International: Lowering the target price of Kingsley Biotech (01548) to HK$27.6 to maintain a “buy” rating

Zhitong FinanceJan 25 11:35

Kingsley Biotechnology (1548.HK): 4Q23 CILTA-CEL sales are in line with expectations, and the main business can recover in 2024 and maintain purchases

交銀國際Jan 24 00:00

Guangfa Securities: Yujinsuri Biotechnology (01548) “buy” rating target price of HK$34.96

Zhitong FinanceNov 24, 2023 09:20

Kingsray Biotechnology (01548.HK): CARVYKTI is expected to accelerate the expansion of the core value of enterprises and repricing

廣發證券Nov 24, 2023 07:22